The rapidly escalating cost of treating colorectal cancer in Australia

Asia-Pacific Journal of Clinical Oncology

Volumn 12, Issue 1, 2016, Pages 33-40

  Ananda, Sumitra ^a,b,c   Kosmider, Suzanne ^b,c   Tran, Ben ^a,c   Field, Kathryn ^a,b   Jones, Ian ^a   Skinner, Iain ^c   Guerrieri, Mario ^d   Chapman, Michael ^a   Gibbs, Peter ^a,b,c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b BioGrid Australia   (Australia)

^c WESTERN HOSPITAL   (Australia)

^d Radiation Oncology Victoria   (Australia)

Author keywords

Colorectal cancer; Cost; Economic evaluation; Prevention; Stage

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; EXPLORATORY RESEARCH; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECURRENCE RISK; SURVIVAL TIME; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; VERY ELDERLY;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AUSTRALIA; BEVACIZUMAB; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES;

EID: 84927603155     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12350     Document Type: Article

References (28)

1. Australian Cancer Incidence and Mortality (ACIM) Books - All Cancers combined for Australia (ICD10 C00-C97, D45-46, D47.1, D47.3). http://www.aihw.gov.au/acim-books/ [Accessed March 2014].
2. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38 (1): 99-166.
3. Australian Institute of Health and Welfare 2012. Cancer incidence projections: Australia, 2011 to 2020. Cancer Series no. 66. Cat. No. CAN 62. Canberra: AIHW.
4. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22 (7): 1209-1214.
5. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352 (5): 476-487.
6. Victoria Public Hospital Policy and Funding Guidelines. 2011-2012. Available from URL: www.health.vic.gov.au/pfg/index201112.htm.
7. Pharmaceutical Benefit Schedule. 2012. Available from URL: http://www.medicareaustralia.gov.au/provider/pbs/index.jsp.
8. Medicare Benefit Schedule. 2012. Available from URL: http://www.medicareaustralia.gov.au/provider/medicare/mbs.jsp.
9. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370 (9604): 2020-2029.
10. Tournigand C, Andre T, Achille E etal. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22 (2): 229-237.
11. Hoff PM, Ansari R, Batist G etal. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19 (8): 2282-2292.
12. Andre T, Boni C, Mounedji-Boudiaf L etal. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350 (23): 2343-2351.
13. Twelves C, Wong A, Nowacki MP etal. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352 (26): 2696-2704.
14. Andre T, Boni C, Navarro M etal. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27 (19): 3109-3116.
15. Hurwitz H, Fehrenbacher L, Novotny W etal. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23): 2335-2342.
16. Saltz LB, Clarke S, Diaz-Rubio E etal. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26 (12): 2013-2019.
17. Tie J, Gibbs P. Erbitux Interim Access Program for the Treatment of Chemotherapy Refractory mCRC: The Australian Nationwide Experience. Abstract presented at Australian GastroIntestinal Trials Group Annual meeting. 2010.
18. Peeters M, Price TJ, Cervantes A etal. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28 (31): 4706-4713.
19. O'Leary BA, Olynyk JK, Neville AM, Platell CF. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol 2004; 19 (1): 38-47.
20. McDermid I. Cancer incidence projections, Australia 2002 to 2011. Canberra: Australian Institute of Health and Welfare (AIHW), Australasian Association of Cancer Registries (AACR) and the National Cancer Strategies Group (NCSG). 2005.
21. Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 2006; 36 (4): 216-220.
22. Kosmider S, Shedda S, Jones IT, McLaughlin S, Gibbs P. Predictors of clinic non-attendance: opportunities to improve patient outcomes in colorectal cancer. Intern Med J 2012; 40 (11): 757-763.
23. Tejpar S, Lenz HJ, Kohne CH etal. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated with cetuximab plus FOLFOX4: New results from the OPUS study. Abstract LBA444 presented at Gastrointestinal Cancers Symposium, 2014.
24. Stintzing S, Jung A, Rossius L etal. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Abstract LBA17 presented at 2013 European Cancer Congress. 2013.
25. Venook AP, Niedzwiecki D, Lenz H-J etal. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum. ASCO Annual Meeting. LBA3. Presented June 2014.
26. Grothey A, Van Cutsem E, Sobrero A etal. Regorafenib monotherapy for previously treated colorectal cancer (CORRECT): an international, multicentre, randomised placebo-controlled phase 3 trial. Lancet 2013; 381 (9863): 303-312.
27. Yoshino T, Mayer R, Falcone A etal. Results of a multicenter, randomized, double-blind, phase III study of TAS-102 vs placebo, with best supportive care in patients with metastatic colorectal cancer refractory to standard therapies. Ann Oncol 2014; 25 (Suppl 2): 114.
28. Ananda SS, McLaughlin SJ, Chen F etal. Initial impact of Australia's National Bowel Cancer Screening Program. Med J Aust 2009; 191 (7): 378-381.